After stratifying by statin, aromatase inhibitor, and glucocorticoid use, we found that the incidence of tendon disorders in the fluoroquinolone group was 60.04, 159.39, and 115.90 per 105 PYs, respectively. This evidence concerns the gene CYP19A1 and disease of the tendon.